NewLink Genetics to Present at Bank of America Merrill Lynch Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Mizuho Securities Cuts Price Target on NewLink Genetics (NLNK) Following Failed IMPRESS Trial
May 10, 2016 1:22 PM EDTMizuho Securities maintained a Buy rating on NewLink Genetics (NASDAQ: NLNK), and cut the price target to $20.00 (from $52.00), following a failed IMPRESS Phase III trial.
Analyst Eric Criscuolo commented, "We reiterate our Buy rating but lower our PT from $52 to $20... More
